Von Hippel-Lindau gene product directs cytokinesis: A new tumor suppressor function

Journal of Cell Science

Volumn 124, Issue 13, 2011, Pages 2132-2142

  Sinha, Sutapa ^a   Mondal, Gourish ^a   Hwang, Eun Ju ^b   Han, Da Woon ^b   Dutta, Shamit K ^a   Iyer, Seethalakshmi ^a   Karumanchi, S Ananth ^c   Kim, Keun Il ^b   Couch, Fergus J ^a   Mukhopadhyay, Debabrata ^a  

^a MAYO CLINIC   (United States)

^b Sookmyung Women's University   (South Korea)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Alix; Cin; Cytokinesis; Endobrevin; Pvhl; SUMOylation

Indexed keywords

ESCRT PROTEIN; GENE PRODUCT; LYSINE; SNARE PROTEIN; UBIQUITIN PROTEIN LIGASE E3; VON HIPPEL LINDAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE REGULATION; CHROMOSOMAL INSTABILITY; CHROMOSOME NUMBER; CONTROLLED STUDY; CYTOKINESIS; DIPLOIDY; ENZYME ACTIVITY; FEMALE; GENE FUNCTION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MOUSE; MUTATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; SUMOYLATION; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE; XENOGRAFT;

ANIMALS; CALCIUM-BINDING PROTEINS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CHROMOSOMAL INSTABILITY; CYTOKINESIS; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; MUTATION; POLYPLOIDY; R-SNARE PROTEINS; SNARE PROTEINS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

MUS;

EID: 79960298137     PISSN: 00219533     EISSN: 14779137     Source Type: Journal    
DOI: 10.1242/jcs.087122     Document Type: Article

References (46)

1. Baker, D. J., Jeganathan, K. B., Malureanu, L., Perez-Terzic, C., Terzic, A. and van Deursen, J. M. (2006). Early aging-associated phenotypes in Bub3/Rae1 haploinsufficient mice. J. Cell Biol. 172, 529-540.
2. Caldwell, C. M., Green, R. A. and Kaplan, K. B. (2007). APC mutations lead to cytokinetic failures in vitro and tetraploid genotypes in Min mice. J. Cell Biol. 178, 1109-1120.
3. Carlton, J. G. and Martin-Serrano, J. (2007). Parallels between cytokinesis and retroviral budding: a role for the ESCRT machinery. Science 316, 1908-912.
4. Chi, Y. H. and Jeang, K. T. (2007). Aneuploidy and cancer. J. Cell. Biochem. 102, 531-538.
5. Cockman, M. E., Masson, N., Mole, D. R., Jaakkola, P., Chang, G. W., Clifford, S. C., Maher, E. R., Pugh, C. W., Ratcliffe, P. J. and Maxwell, P. H. (2000). Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275, 25733-25741.
6. Crossey, P. A., Richards, F. M., Foster, K., Green, J. S., Prowse, A., Latif, F., Lerman, M. I., Zbar, B., Affara, N. A., Ferguson-Smith, M. A. et al. (1994). Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum. Mol. Genet., 1303-1308.
7. Daniels, M. J., Wang, Y., Lee, M. and Venkitaraman, A. R. (2004). Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 306, 876-879.
8. Fabbro, M., Zhou, B. B., Takahashi, M., Sarcevic, B., Lal, P., Graham, M. E., Gabrielli, B. G., Robinson, P. J., Nigg, E. A., Ono, Y. et al. (2005). Cdk1/Erk2- and Plk1-dependent phosphorylation of a centrosome protein, Cep55, is required for its recruitment to midbody and cytokinesis. Dev. Cell 9, 477-88.
9. Fujiwara, T., Bandi, M., Nitta, M., Ivanova, E. V., Bronson, R. T. and Pellman, D. (2005). Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 437, 1043-1047.
10. Giles, R. H. and Voest, E. E. (2005). Tumor suppressors APC and VHL: gatekeepers of the intestine and kidney. In Development Biology of Neoplastic Growth, Vol. 40 (ed. A. M. Coelho), pp. 151-181. Utrecht: Springer Berlin Heidelberg.
11. Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F. M. et al. (1994). Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85-90.
12. Gnarra, J. R., Zhou, S., Merrill, M. J., Wagner, J. R., Krumm, A., Papavassiliou, E., Oldfield, E. H., Klausner, R. D. and Linehan, W. M. (1996). Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl. Acad. Sci. USA 93, 0589-10594.
13. He, Z., Liu, S., Guo, M., Mao, J. and Hughson, M. D. (2004). Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation. Cancer Genet. Cytogenet. 152, 89-94.
14. Hergovich, A., Lisztwan, J., Barry, R., Ballschmieter, P. and Krek, W. (2003). Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat. Cell Biol. 5, 64-70.
15. Hoebeeck, J., van der Luijt, R., Poppe, B., De Smet, E., Yigit, N., Claes, K., Zewald, R., de Jong, G. J., De Paepe, A., Speleman, F. et al. (2005). Rapid detection of VHL exon deletions using real-time quantitative PCR. Lab. Invest. 85, 24-33.
16. Iliopoulos, O., Kibel, A., Gray, S. and Kaelin, W. G., Jr. (1995). Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1, 22-826.
17. Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G., Jr and Goldberg, M. A. (1996). Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA 93, 10595-10599.
18. Kim, W. Y. and Kaelin, W. G. (2004). Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22, 4991-5004.
19. Levy, A. P., Levy, N. S. and Goldberg, M. A. (1996). Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J. Biol. Chem. 271, 25492-25497.
20. Lolkema, M. P., Mehra, N., Jorna, A. S., van Beest, M., Giles, R. H. and Voest, E. E. (2004). The von Hippel-Lindau tumor suppressor protein influences microtubule dynamics at the cell periphery. Exp. Cell Res. 301, 139-146.
21. Low, S. H., Li, X., Miura, M., Kudo, N., Quinones, B. and Weimbs, T. (2003). Syntaxin 2 and endobrevin are required for the terminal step of cytokinesis in mammalian cells. Dev. Cell 4, 753-759.
22. Maher, E. R. and Kaelin, W. G., Jr. (1997). von Hippel-Lindau disease. Medicine (Baltimore). 76, 381-391.
23. Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R. and Ratcliffe, P. J. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275.
24. Morita, E., Sandrin, V., Chung, H. Y., Morham, S. G., Gygi, S. P., Rodesch, C. K. and Sundquist, W. I. (2007). Human ESCRT and ALIX proteins interact with proteins of the midbody and function in cytokinesis. EMBO J. 26, 4215-4227.
25. Ohh, M., Yauch, R. L., Lonergan, K. M., Whaley, J. M., Stemmer-Rachamimov, A. O., Louis, D. N., Gavin, B. J., Kley, N., Kaelin, W. G., Jr and Iliopoulos, O. (1998). The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1, 59-968.
26. Ozcan, A., Shen, S. S., Zhai, Q. J. and Truong, L. D. (2007). Expression of GLUT1 in primary renal tumors: morphologic and biologic implications. Am. J. Clin. Pathol. 128, 245-254.
27. Pichiorri, F., Suh, S. S., Ladetto, M., Kuehl, M., Palumbo, T., Drandi, D., Taccioli, C., Zanesi, N., Alder, H., Hagan, J. P. et al. (2008). MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc. Natl. Acad. Sci. USA 105, 12885-12890.
28. Richards, F. M., Phipps, M. E., Latif, F., Yao, M., Crossey, P. A., Foster, K., Linehan, W. M., Affara, N. A., Lerman, M. I., Zbar, B. et al. (1993). Mapping the Von Hippel-Lindau disease tumour suppressor gene: identification of germline deletions by pulsed field gel electrophoresis. Hum. Mol. Genet. 2, 79-882.
29. Richards, F. M., Crossey, P. A., Phipps, M. E., Foster, K., Latif, F., Evans, G., Sampson, J., Lerman, M. I., Zbar, B., Affara, N. A. et al. (1994). Detailed mapping of germline deletions of the von Hippel-Lindau disease tumour suppressor gene. Hum. Mol. Genet. 3, 595-598.
30. Rodriguez, M. S., Dargemont, C. and Hay, R. T. (2001). SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J. Biol. Chem. 276, 12654-12659.
31. Roe, J. S., Kim, H., Lee, S. M., Kim, S. T., Cho, E. J. and Youn, H. D. (2006). p53 stabilization and transactivation by a von Hippel-Lindau protein. ol. Cell 22, 395-405.
32. Sampson, D. A., Wang, M. and Matunis, M. J. (2001). The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J. Biol. Chem. 276, 21664-21669.
33. Schoenfeld, A., Davidowitz, E. J. and Burk, R. D. (1998). A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc. Natl. Acad. Sci. USA 95, 8817-8822.
34. Siemeister, G., Weindel, K., Mohrs, K., Barleon, B., Martiny-Baron, G. and Marme, D. (1996). Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 56, 2299-2301.
35. Sinha, S., Cao, Y., Dutta, S., Wang, E. and Mukhopadhyay, D. (2008). VEGF neutralizing antibody increases the therapeutic efficacy of vinorelbine for renal cell carcinoma. J. Cell. Mol. Med. 14, 647-658.
36. Sinha, S., Dutta, S., Datta, K., Ghosh, A. K. and Mukhopadhyay, D. (2009a). Von Hippel-Lindau gene product modulates TIS11B expression in renal cell carcinoma: impact on vascular endothelial growth factor expression in hypoxia. J. Biol. Chem. 284, 32610-32618.
37. Sinha, S., Vohra, P. K., Bhattacharya, R., Dutta, S., Sinha, S. and Mukhopadhyay, D. (2009b). Dopamine regulates phosphorylation of VEGF receptor 2 by engaging Srchomology-2-domain-containing protein tyrosine phosphatase 2. J. Cell Sci. 122, 3385-3392.
38. Stebbins, C. E., Kaelin, W. G., Jr and Pavletich, N. P. (1999). Structure of the VHLElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284, 455-461.
39. Stolle, C., Glenn, G., Zbar, B., Humphrey, J. S., Choyke, P., Walther, M., Pack, S., Hurley, K., Andrey, C., Klausner, R. et al. (1998). Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum. Mutat. 12, 417-423.
40. Strack, B., Calistri, A., Craig, S., Popova, E. and Gottlinger, H. G. (2003). AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 114, 689-699.
41. Thoma, C. R., Toso, A., Gutbrodt, K. L., Reggi, S. P., Frew, I. J., Schraml, P., Hergovich, A., Moch, H., Meraldi, P. and Krek, W. (2009). VHL loss causes spindle misorientation and chromosome instability. Nat. Cell Biol. 11, 994-1001.
42. von Schwedler, U. K., Stuchell, M., Muller, B., Ward, D. M., Chung, H. Y., Morita, E., Wang, H. E., Davis, T., He, G. P., Cimbora, D. M. et al. (2003). The protein network of HIV budding. Cell 114, 701-713.
43. Wu, X., Mondal, G., Wang, X., Wu, J., Yang, L., Pankratz, V. S., Rowley, M. and Couch, F. J. (2009). Microcephalin regulates BRCA2 and Rad51-associated DNA double-strand break repair. Cancer Res. 69, 5531-5536.
44. Zbar, B., Kishida, T., Chen, F., Schmidt, L., Maher, E. R., Richards, F. M., Crossey, P. A., Webster, A. R., Affara, N. A., Ferguson-Smith, M. A. et al. (1996). Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum. Mutat. 8, 348-357.
45. Zhou, M. I., Wang, H., Ross, J. J., Kuzmin, I., Xu, C. and Cohen, H. T. (2002). The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1. J. Biol. Chem. 277, 39887-39898.
46. Zhou, M. I., Wang, H., Foy, R. L., Ross, J. J. and Cohen, H. T. (2004). Tumor suppressor von Hippel-Lindau (VHL) stabilization of Jade-1 protein occurs through plant homeodomains and is VHL mutation dependent. Cancer Res. 64, 1278-1286.